New Drugs

  • Promising pipeline for chronic pruritus

    on January 13th, 2017
    EXPERT ANALYSIS FROM THE EADV CONGRESS VIENNA (FRONTLINE MEDICAL NEWS) – Help is on the way for physicians stymied in their efforts to treat patients with severe chronic itch, Sonja Ständer, MD, declared at the annual congress of the European Academy of Dermatology and Venereology. Now working th[...]
  • CVS selling low-cost generic epinephrine autoinjector

    on January 12th, 2017
    CVS Pharmacy is currently selling a generic epinephrine autoinjector for a price of $109.99 per two-pack, which is about one-sixth the cost of Mylan’s EpiPen two-pack. The product, an authorized generic for Adrenaclick,is manufactured by Lineage Therapeutics, which is a wholly owned subsidiary of [...]
  • Circulating microRNAs may predict breast cancer treatment response

    on January 12th, 2017
    AT SABCS 2016 SAN ANTONIO (FRONTLINE MEDICAL NEWS) – Circulating microRNAs may predict treatment response in HER2-positive breast cancer patients treated with neoadjuvant therapy, according to findings from the randomized phase III NeoALTTO trial. Specifically, four circulating tumor microRNA sign[...]
  • 177Lu-Dotatate for advanced midgut neuroendocrine tumors

    on January 12th, 2017
    FROM THE NEW ENGLAND JOURNAL OF MEDICINE 177Lu-Dotatate, a radionuclide related to octreotide, reduced the risk of disease progression or death by 79% in a phase III trial involving 229 adults with advanced, progressive midgut neuroendocrine tumors, investigators reported in the New England Journal [...]
  • Ladostigil advances to phase III after hints of slowing brain atrophy in MCI patients

    on December 20th, 2016
    AT CTAD SAN DIEGO (FRONTLINE MEDICAL NEWS) – Ladostigil, a drug that combines molecular characteristics of rivastigmine and rasagiline, was associated with some modest memory improvement and – perhaps more interestingly – a signal of brain volume preservation in a phase IIb study of patients w[...]
  • FDA approves rucaparib for BRCA-positive advanced ovarian cancer

    on December 19th, 2016
    The Food and Drug Administration has granted accelerated approval to rucaparib for the treatment of women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a germline or somatic BRCA gene mutation. The FDA also approved the FoundationFocus CDxBR[...]
  • Phase I results move Alzheimer’s candidate drug aducanumab into phase III trials

    on December 19th, 2016
    AT CTAD SAN DIEGO (FRONTLINE MEDICAL NEWS) – The antiamyloid antibody aducanumab significantly reduced amyloid brain plaques in Alzheimer’s disease patients who entered a second year of therapy in an open-label extension trial. Plaque volume declined in a time- and dose-dependent manner, with a [...]
  • Sigma-1 agonist presses forward after positive results in small Alzheimer’s trial

    on December 13th, 2016
    AT CTAD SAN DIEGO (FRONTLINE MEDICAL NEWS) – A novel Alzheimer’s disease drug candidate appeared to stabilize cognition and function over 57 weeks in a small, early-phase, open-label trial. Patients with mild to moderate Alzheimer’s who took ANAVEX 2-73, an agonist of the sigma-1 receptor, exp[...]
  • Nivolumab plus ipilimumab shines as first-line in advanced NSCLC

    on December 6th, 2016
    AT WCLC 2016 VIENNA (FRONTLINE MEDICAL NEWS) – The combination of nivolumab and ipilimumab as first-line therapy in patients with advanced non–small cell lung cancer (NSCLC) doubled median progression-free survival time compared with nivolumab monotherapy in updated results from the CheckMate 01[...]
  • Phase II trial: Drug reduces sickle cell ‘pain crises’

    on December 4th, 2016
    FROM ASH 2016 An industry-funded phase II trial has shown that high doses of the experimental drug crizanlizumab significantly reduced the number of dangerous “pain crises” in subjects with sickle cell disease. The median per-year rate of pain crises was 45.3% lower among those who took the high[...]
  • VIDEO: Novel microcapsules show promise in hemophilia A with inhibitory antibodies

    on December 4th, 2016
    AT ASH 2016 SAN DIEGO (FRONTLINE MEDICAL NEWS) – Novel microcapsules loaded with factor VIII outperformed systemic factor VIII infusions in models of hemophilia A with inhibitory antibodies, Caroline E. Hansen reported at the annual meeting of the American Society of Hematology. “This is a compl[...]
  • Biosimilar trastuzumab shows similar efficacy

    on December 1st, 2016
    FROM JAMA A trastuzumab biosimilar drug has shown an equivalent response, compared with trastuzumab, in the treatment of ERBB2 (HER2)-positive metastatic breast cancer, according to the results of a randomized double-blind controlled trial. The anti-ERBB2 humanized monoclonal antibody trastuzumab in[...]
  • Dapivirine vaginal ring cuts new HIV-1 infections

    on November 30th, 2016
    FROM THE NEW ENGLAND JOURNAL OF MEDICINE The dapivirine vaginal ring reduced the rate of new HIV-1 infection by 31% in a phase III clinical trial involving 1,959 high-risk women in sub-Saharan Africa, according to a report published in the New England Journal of Medicine. The dapivirine-containing r[...]
Back to top